Literature DB >> 9024727

Comparison of dobutamine stress echocardiography and 99m-technetium sestamibi SPECT myocardial perfusion scintigraphy for predicting extent of coronary artery disease in patients with healed myocardial infarction.

A Elhendy1, M L Geleijnse, J R Roelandt, R T van Domburg, F J Ten Cate, P R Nierop, J J Bax, M El-Refaee, M M Ibrahim, G M El-Said, P M Fioretti.   

Abstract

This study compares the value of dobutamine stress echocardiography and 99m-technetium methoxyisobutyl-isonitrile (MIBI) single-photon emission computed tomography (SPECT) in the assessment of extent and location of coronary narrowing in patients with healed myocardial infarction. Dobutamine (up to 40 microg/kg/ min)-atropine (up to 1 mg) stress echocardiography (DSE) in conjunction with MIBI SPECT was performed in 72 patients (52 men, mean age 57 +/- 11 years) with healed myocardial infarction referred for evaluation of myocardial ischemia. Ischemia was defined as new or worsened wall motion abnormalities at DSE and reversible perfusion defects at MIBI SPECT. Significant stenosis (> or = 50% luminal diameter stenosis) of the infarct-related artery was detected in 45 patients and of other coronary arteries in 22 patients. Sensitivity and specificity of remote ischemia for diagnosis of remote coronary stenosis were 68% (95% confidence interval [CI] 57 to 80) and 93% (CI 86 to 99) for DSE, and 64% (CI 52 to 76), and 90% (CI 83 to 98) for MIBI SPECT, respectively. The positive predictive value and specificity of peri-infarction ischemia for the diagnosis of infarct-related artery stenosis were 89% (CI 81 to 97) and 82% (CI 73 to 92) for DSE, and 87% (CI 79 to 95) and 82% (CI 73 to 92) for SPECT, respectively. The agreement between both techniques was higher for the diagnosis of remote than peri-infarction ischemia (84% vs 66%, p = 0.02). It is concluded that in patients with myocardial infarction undergoing dobutamine stress testing, both echocardiography and MIBI SPECT are clinically useful methods for the diagnosis of remote and infarct-related coronary artery stenosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9024727     DOI: 10.1016/s0002-9149(96)00667-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Prognostic value of stress Tc-99m tetrofosmin SPECT in patients with previous myocardial infarction: impact of scintigraphic extent of coronary artery disease.

Authors:  Abdou Elhendy; Arend F L Schinkel; Ron T van Domburg; Jeroen J Bax; Roelf Valkema; Don Poldermans
Journal:  J Nucl Cardiol       Date:  2004 Nov-Dec       Impact factor: 5.952

2.  Mechanisms of regional wall motion abnormalities in contrast-enhanced dobutamine stress echocardiography.

Authors:  N Heinicke; B Benesch; T Kaiser; K Debl; M Segmüller; J Schönberger; J Marienhagen; C Eilles; G A J Riegger; S Holmer; A Luchner
Journal:  Clin Res Cardiol       Date:  2006-09-28       Impact factor: 5.460

3.  Comparison of dobutamine stress echocardiography and exercise stress Thallium-201 SPECT for detection of myocardial ischemia after acute myocardial infarction treated with thrombolysis.

Authors:  M Previtali; G Cannizzaro; L Lanzarini; G Calsamiglia; A Poli; R Fetiveau
Journal:  Int J Card Imaging       Date:  1999-06

4.  Dobutamine stress echocardiography versus quantitative technetium-99m sestamibi SPECT for detecting residual stenosis and multivessel disease after myocardial infarction.

Authors:  P Lancellotti; T Benoit; P Rigo; L A Pierard
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

5.  Dobutamine-atropine stress myocardial perfusion SPECT imaging in the diagnosis of graft stenosis after coronary artery bypass grafting.

Authors:  A Elhendy; R T van Domburg; J J Bax; P R Nierop; R Valkema; M L Geleijnse; J D Kasprzak; A F Liqui-Lung; J H Cornel; J R Roelandt
Journal:  J Nucl Cardiol       Date:  1998 Sep-Oct       Impact factor: 5.952

6.  Stress echocardiography for the diagnosis of coronary artery disease: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2010-06-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.